Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
1773
mi
from 98109
Centralia, IL
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1773
mi
from 98109
Centralia, IL
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2095
mi
from 98109
Metairie, LA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2095
mi
from 98109
Metairie, LA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2317
mi
from 98109
Chevy Chase, MD
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2317
mi
from 98109
Chevy Chase, MD
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2485
mi
from 98109
Boston, MA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2485
mi
from 98109
Boston, MA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
1720
mi
from 98109
St Louis, MO
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1720
mi
from 98109
St Louis, MO
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2392
mi
from 98109
Lebanon, NH
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2392
mi
from 98109
Lebanon, NH
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2387
mi
from 98109
West Orange, NJ
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2387
mi
from 98109
West Orange, NJ
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
1184
mi
from 98109
Albuquerque, NM
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1184
mi
from 98109
Albuquerque, NM
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2353
mi
from 98109
Albany, NY
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2353
mi
from 98109
Albany, NY
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2281
mi
from 98109
Charlotte, NC
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2281
mi
from 98109
Charlotte, NC
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
1931
mi
from 98109
Lima, OH
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1931
mi
from 98109
Lima, OH
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
367
mi
from 98109
Medford, OR
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
367
mi
from 98109
Medford, OR
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2373
mi
from 98109
Philadelphia, PA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2373
mi
from 98109
Philadelphia, PA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2486
mi
from 98109
Providence, RI
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2486
mi
from 98109
Providence, RI
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2423
mi
from 98109
Charleston, SC
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2423
mi
from 98109
Charleston, SC
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
1971
mi
from 98109
Nashville, TN
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1971
mi
from 98109
Nashville, TN
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
2351
mi
from 98109
Richmond, VA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2351
mi
from 98109
Richmond, VA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Clinical Trial Facility
10
mi
from 98109
Mountlake Terrace, WA
VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection.
A Randomized, Open-label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naive Subjects With Genotype 1 Chronic Hepatitis C Virus Infection.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
10
mi
from 98109
Mountlake Terrace, WA
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection
Status: Archived
Local Institution
967
mi
from 98109
Inglewood, CA
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection
Status: Archived
Updated: 1/1/1970
Local Institution
967
mi
from 98109
Inglewood, CA
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Clinical Trial Facility
711
mi
from 98109
Santa Clara, CA
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
711
mi
from 98109
Santa Clara, CA
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Hematology Oncology Associates of the Quad Cities
1609
mi
from 98109
Bettendorf, IA
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
1609
mi
from 98109
Bettendorf, IA
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir
A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state
Status: Archived
Clinical Trial Facility
2387
mi
from 98109
West Orange, NJ
VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir
A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2387
mi
from 98109
West Orange, NJ
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated:  12/31/1969
Holy Cross Hospital of Silver Spring
2318
mi
from 98109
Silver Spring, MD
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated: 12/31/1969
Holy Cross Hospital of Silver Spring
2318
mi
from 98109
Silver Spring, MD
Click here to add this to my saved trials
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated:  12/31/1969
Occupational Medicine Services
2317
mi
from 98109
Annandale, VA
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated: 12/31/1969
Occupational Medicine Services
2317
mi
from 98109
Annandale, VA
Click here to add this to my saved trials
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated:  12/31/1969
Inova Fairfax Hospital
2314
mi
from 98109
Falls Church, VA
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated: 12/31/1969
Inova Fairfax Hospital
2314
mi
from 98109
Falls Church, VA
Click here to add this to my saved trials
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated:  12/31/1969
MedStar Washington Hospital Center
2322
mi
from 98109
Washington,
Immune Response to Hepatitis C Virus
Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus
Status: Enrolling
Updated: 12/31/1969
MedStar Washington Hospital Center
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated:  12/31/1969
University of Arkansas
1782
mi
from 98109
Little Rock, AR
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated: 12/31/1969
University of Arkansas
1782
mi
from 98109
Little Rock, AR
Click here to add this to my saved trials
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated:  12/31/1969
University of Tennessee
1865
mi
from 98109
Memphis, TN
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated: 12/31/1969
University of Tennessee
1865
mi
from 98109
Memphis, TN
Click here to add this to my saved trials
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
1970
mi
from 98109
Nashville, TN
Racial Difference in HCV/Host Interactions
African American Response to Therapy for Hepatitis C
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
Baylor University
1729
mi
from 98109
Dallas, TX
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Baylor University
1729
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
University of Colorado
1023
mi
from 98109
Denver, CO
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
University of Colorado
1023
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
Northwestern University
1733
mi
from 98109
Chicago, IL
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Northwestern University
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
University of Michigan
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
2
mi
from 98109
Seattle, WA
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
2485
mi
from 98109
Boston, MA
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Transplant Patient Registry of Liver, Kidney and/or Pancreas
Transplant Registry: Patients Who May Require Transplantation and Those Who Have Undergone Transplantation of Liver, Kidney and/or Pancreas
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Health System
2352
mi
from 98109
Richmond, VA
Transplant Patient Registry of Liver, Kidney and/or Pancreas
Transplant Registry: Patients Who May Require Transplantation and Those Who Have Undergone Transplantation of Liver, Kidney and/or Pancreas
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Health System
2352
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
University of Arizona Health Sciences Center
1220
mi
from 98109
Tucson, AZ
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
University of Arizona Health Sciences Center
1220
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
Veterans Administration Long Beach Medical Center
979
mi
from 98109
Long Beach, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
Veterans Administration Long Beach Medical Center
979
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
Veterans Administration Los Angeles Healthcare System
959
mi
from 98109
Los Angeles, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
Veterans Administration Los Angeles Healthcare System
959
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
Chao Family Comprehensive Cancer Center
984
mi
from 98109
Orange, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
Chao Family Comprehensive Cancer Center
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated:  12/31/1969
University of California, San Diego
1049
mi
from 98109
San Diego, CA
Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP
Status: Enrolling
Updated: 12/31/1969
University of California, San Diego
1049
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Hepatitis C Treatment and Atherosclerosis
Hepatitis C Eradication and Progression of Atherosclerosis
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Hepatitis C Treatment and Atherosclerosis
Hepatitis C Eradication and Progression of Atherosclerosis
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
A Pilot Study of Therapy With Pioglitazone Prior to HCV Treatment in HIV-1 and HCV Genotype 1-Infected Subjects With Insulin Resistance Who Are Prior Nonresponders to Peginterferon and Ribavirin Therapy
Status: Enrolling
Updated:  12/31/1969
Ucsf Aids Crs (801)
680
mi
from 98109
San Francisco, CA
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
A Pilot Study of Therapy With Pioglitazone Prior to HCV Treatment in HIV-1 and HCV Genotype 1-Infected Subjects With Insulin Resistance Who Are Prior Nonresponders to Peginterferon and Ribavirin Therapy
Status: Enrolling
Updated: 12/31/1969
Ucsf Aids Crs (801)
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials